André Abrahão
André Abrahão is the Medical Director of Gilead Sciences Brazil, where he plays a crucial role in the development and introduction of innovative treatments for HIV, including lenacapavir, an injectable medication approved by Anvisa for its potential to prevent HIV infections and treat patients with limited therapeutic options.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Brazil | 2 | 8.00 | 0.18% | +0% | 211,049,527 | 378,564 | $1,500,000 | 2,691$ |
| Totals | 2 | 211,049,527 | 378,564 | $1,500,000 | 2,691$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Brazil:
André Abrahão is the Medical Director of Gilead Sciences Brazil and emphasizes the long-term innovation of lenacapavir in expanding prevention options.
8
Brazil:
André Abrahão is the Medical Director of Gilead Sciences Brazil and emphasizes the long-term innovation of lenacapavir in expanding prevention options.
8